Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 143 No. 4344 (2013)

Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care

  • Hans Hendrik Schäfer
  • Uta Scheunert
Cite this as:
Swiss Med Wkly. 2013;143:w13854


  1. Simpson FO. Long-term cost and life-expectancy consequences of hypertension. J Hypertens. 1998;16:1099–100.
  2. Leone A. The Economic Costs for the Control of Cardiovascular Risk: An Overview. Current Pharmaceutical Design. 2013;19(13):2447–53.
  3. Aronow WS. Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events. Am J Ther. 2013 (epub ahead of print).
  4. Karakurt P, Kasikci M. Factors affecting medication adherence in patients with hypertension. Journal of vascular nursing: official publication of the Society for Peripheral Vascular Nursing 2012;30:118–26.
  5. Chrostowska M, Narkiewicz K. Improving patient compliance with hypertension treatment: mission possible? Curr Vasc Pharmacol. 2010;8:804–7.
  6. LaFleur J, Oderda GM. Methods to measure patient compliance with medication regimens. J Pain Palliat Care Pharmacother. 2004;18:81–7.
  7. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. The Ann Pharmacother. 2002;36:1331–6.
  8. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens. (Greenwich) 2011;13:898–909.
  9. Jackson K. Persistence of fixed versus free combination with valsartan and HCTZ for patients with hypertension. Value Health Suppl. 2006;9:A363.
  10. Schafer HH, Sudano I, Theus GR, Noll G, Burnier M. Target blood pressure attainment with antihypertensive therapy in Swiss primary care. Blood pressure. 2012;21:211–9.
  11. Schafer HH, Sudano I, Theus GR, Zilla P, Noll G, Burnier M. Blood pressure target attainment in the background of guidelines: the very elderly in Swiss primary care. Fam Pract. 2012;29:511–20.
  12. Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ. 1999;18:681–708.
  13. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig. 2008;28:713–34.
  14. Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin. 2012;28:1685–97.
  15. Schweizereische Eidgenossenschaft BfS. Gesundheitsdienste und Personal, Andere ambulante Dienste – Indikatoren. Ärzte und Zahnärzte 2011.
  16. Swiss Society of Hypertension. Arterielle Hypertonie, Empfehlungen für Ärzte, Expertenmeinung ohne Haftung., last access date 29.08.2013.
  17. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical therapeutics. 2001;23:1296–310.
  18. Schweizerische Eidgenossenschaft, Bundesamt für Statistik. Schätzungen zur Bevölkerung der Schweiz 2012., last access date 29.08.2013.
  19. Schweizerische Herzstiftung. Zahlen und Fakten zum Bluthochdruck. 2007., last access date 29.08.2013.
  20. Schweizerische Eidgenossenschaft BfS. Bevölkerungsstand und -struktur – Indikatoren, Bevölkerung nach Alter, Ständige Wohnbevölkerung nach Alter am Jahresende 2012. In; 2012
  21. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA: the journal of the American Medical Association 2003;289:2363–9.
  22. Edwards PR, Lunt DW, Fehrsen GS, Lombard CJ, Steyn K. Improving cost-effectiveness of hypertension management at a community health centre. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1998;88:549–54.
  23. Ilesanmi OS, Ige OK, Adebiyi AO. The managed hypertensive: the costs of blood pressure control in a Nigerian town. Pan Afr Med J. 2012;12:96.
  24. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health. 1996;86:1805–8.
  25. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens. 2004;22:1831–7.
  26. Coca A. Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers). Clin Drug Investig. 2008;28:211–20.
  27. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Journal of the renin-angiotensin-aldosterone system: JRAAS 2012;13:387–93.
  28. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review. Cardiovasc Diabetol. 2009;8:18.
  29. Breitscheidel L, Ehlken B, Kostev K, Oberdiek MS, Sandberg A, Schmieder RE. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. J Med Econ. 2012;15:155–65.
  30. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. Journal of hypertension Supplement: official journal of the International Society of Hypertension 2001;19:S33–40.
  31. Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood pressure. 2007;16:135–232.
  32. Schafer HH, de Villiers JD, Sudano I, Theus GR, Sivukhina E, Burnier M, et al. Management of hypertension in patients with diabetes mellitus and metabolic syndrome in Swiss primary care. Int J Clin Pract. 2012;66:1125–6.
  33. Rochefort CM, Morlec J, Tamblyn RM. What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study. BMC family practice. 2012;13:9.
  34. Grimm C, Koberlein J, Wiosna W, Kresimon J, Kiencke P, Rychlik R. New-onset diabetes and antihypertensive treatment. GMS health technology assessment 2010;6:doc03. doi: 10.3205/hta000081.
  35. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005; 11 Spec No: SP27–34
  36. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Medical care. 1994;32:214–26.

Most read articles by the same author(s)